RedHill

RedHill Replaces its Co-Commercialization Agreement with Daiichi Sankyo for Movantik (naloxegol)

  • by

Shots: The new agreement involves, Daiichi to get royalties on sales of Movantik plus payments each year starting from 2021 to 2023. RedHill to take care of all the responsibilities and costs to commercialize Movantik in the US. Additionally, under a subscription agreement Daiichi will… Read More »RedHill Replaces its Co-Commercialization Agreement with Daiichi Sankyo for Movantik (naloxegol)